We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+20.92%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.42B
AUM Growth
+$350M
Cap. Flow
+$135M
Cap. Flow %
5.56%
Top 10 Hldgs %
42.31%
Holding
83
New
4
Increased
11
Reduced
18
Closed
3

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$67.3M
2
THRD
Third Harmonic Bio
THRD
+$63.1M
3
RVMD icon
Revolution Medicines
RVMD
+$22M
4
ALLK
Allakos
ALLK
+$21M
5
VERV
Verve Therapeutics
VERV
+$20.7M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$32.9M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$25.1M
3
EQRX
EQRx, Inc. Common Stock
EQRX
+$23.4M
4
MRUS
Merus
MRUS
+$15.2M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHXM
76
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$690K 0.03%
131,466
– –
NEUP
77
Neuphoria Therapeutics
NEUP
$21.1M
$578K 0.02%
6,748
– –
GLMD icon
78
Galmed Pharmaceuticals
GLMD
$4.82M
$558K 0.02%
9,998
– –
RZLT icon
79
Rezolute
RZLT
$454M
$523K 0.02%
190,815
– –
CFRX
80
DELISTED
ContraFect Corporation
CFRX
$79K ﹤0.01%
5,904
-43,750
-88% -$2.21M
CLDX icon
81
Celldex Therapeutics
CLDX
$2.96B
– –
-154,000
Closed -$4.15M
PTGX icon
82
Protagonist Therapeutics
PTGX
$8.7B
– –
-1,106,838
Closed -$8.76M
VYGR icon
83
Voyager Therapeutics
VYGR
$185M
– –
-140,000
Closed -$827K
1 2 3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2022 Portfolio in Review

As of Q3 2022, BVF Inc held 83 positions worth $2.42B, up 17% from $2.07B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

BVF Inc deployed $135M of net new capital in Q3 2022, opening 4 new positions and adding to 11 existing holdings. Its largest new stake was Third Harmonic Bio: 3,501,814 shares worth $66.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $32.9M trimmed.

  • BVF Inc's largest Q3 2022 buy was Third Harmonic Bio: 3,501,814 shares worth $66.4M.
  • BVF Inc added most to Ionis Pharmaceuticals in Q3 2022, an estimated $67.3M increase.
  • BVF Inc's biggest Q3 2022 reduction was Arcus Biosciences, cutting an estimated $32.9M.
  • BVF Inc fully exited Protagonist Therapeutics in Q3 2022, selling an estimated $8.76M.
  • BVF Inc's ten largest holdings make up 42% of its $2.42B portfolio in Q3 2022.
  • BVF Inc opened 4 new positions and closed 3 in Q3 2022.
  • BVF Inc's portfolio value rose 17% quarter-over-quarter to $2.42B.

Based on BVF Inc's 13F filing for Q3 2022, filed 14 Nov 2022.